Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

TIGECYCLINE

All injection strengths: general benefit

Other products in the same Health Canada class (J01AA) — coverage varies; not interchangeable

  • Doxycycline hyclate (PMS-Doxycycline): general benefit, Not a benefit
  • Minocycline (Minocycline): general benefit, Not a benefit
  • Tetracycline (Tetracyn): general benefit, Not a benefit
  • Doxycycline (Apprilon): not a benefit

Tygacil · DIN 02285401 · 50mg/Vial · Pd for injection-5mLVial Pk (Preservative-Free)

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Tygacil · DIN 02285401 Manufacturer: Pfizer Canada Inc.; listing date 2014-11-27 Health Canada: Marketed since 2012-04-17 · brand TYGACIL · ATC J01AA12 TIGECYCLINE · form Powder for solution · route Intravenous · ingredients TIGECYCLINE 50 MG/VIAL · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Tygacil: Formulary list price $83.4740/unit (unit not stated in source; not the patient's cost)

Ministry pays: $83.4740 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77090 · Verify on the e-Formulary ↗ (DIN 02285401)

Source record
DIN 02285401: Tygacil Raw flags: sec3=Y Item: 081224020; group id 35; item number 0071; lccId None; manufacturer id PFI Source form: Pd for Inj-5mLVial Pk (Preservative-Free); strength: 50mg/Vial Recorded listing: General benefit Source prices (unrounded): $83.4740; ministry $83.4740 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02285401 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77090
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02285401
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (08:12:24 Tetracyclines) and how they are covered

Matched class: 08:12:24 Tetracyclines

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): DOXYCYCLINE HYCLATE, MINOCYCLINE HCL, TETRACYCLINE 08:12:24 Tetracyclines

DOXYCYCLINE HYCLATE

· 10 products · Off-Formulary Interchangeable, not an ODB benefit (2), Listed, not a benefit (1), General benefit (7) · strengths: 20mg, 100mg · Cap, Tab

MINOCYCLINE HCL

· 4 products · General benefit (2), Listed, not a benefit (2) · strengths: 50mg, 100mg · Cap

TETRACYCLINE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 250mg · Cap

DOXYCYCLINE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 40mg · MR Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:12:24
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:16 Penicillins, 08:12:28 Other Antibiotics, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 Indications TYGACIL (tigecycline) is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms in patients 18 years of age and older: • Complicated skin and skin structure infections (cSSSI) caused by Escherichia coli, Enterococcus faecalis (vancomycinsusceptible strains only), Staphylococcus aureus (methicillin susceptible and - resistant strains), Streptococcus agalactiae, Streptococcus anginosus, Streptococcus pyogenes, Enterobacter cloacae, Klebsiella pneumoniae, and Bacteroides fragilis. Patients with severe underlying disease, such as those who were immunocompromised, patients with decubitus ulcer infections, or patients who had infections requiring longer than 14 days of treatment (for example, necrotizing fasciitis), were not enrolled in clinical trials. • Complicated intraabdominal infections (cIAI) caused by Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Enterococcus faecalis (vancomycin- susceptible strains only), Staphylococcus aureus (methicillin-susceptible only), Streptococcus anginosus grp. (includes… https://pdf.hres.ca/dpd_pm/00082316.PDF PM date: not printed or not captured Source product: TYGACIL; DIN 02285401; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.